Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies

• Published in: Journal of cutaneous medicine and surgery Vol. 26; no. 1_suppl; pp. 3S - 23S
• Main Authors: Yeung, Jensen, Bunce, Paul E., Lynde, Charles W., Turchin, Irina, Vender, Ronald B.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-07-2022; SAGE PUBLICATIONS, INC
• Subjects: anti-IL-17; biologics; candidiasis; management; psoriasis
• ISSN: 1203-4754; 1615-7109
• DOI: 10.1177/12034754221111111

The IL-17 signalling pathway is a major target in treatment of plaque psoriasis. IL-17 signalling contributes to chronic inflammation and epidermal hyperplasia seen in psoriatic lesions. Blocking the IL-17 signalling cascade is an effective method in treating this disease. However, IL-17 also plays a role in the immunological protection against fungal infections and therefore, patients on IL-17 biologics experience an increased rate of fungal infections, specifically Candida albicans. It is prudent that patients and physicians are aware of this risk and understand how to recognize and manage Candida infections. In this review, we examine the Candida infection rates associated with IL-17 biologics, both in clinical trials and real-world practice. We discuss common presentations associated with various types of candidiasis and propose a recommended management approach to treating these infections.